Equities

Laboratorio Reig Jofre SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Laboratorio Reig Jofre SA

Actions
  • Price (EUR)2.67
  • Today's Change0.00 / 0.00%
  • Shares traded9.52k
  • 1 Year change+0.38%
  • Beta0.8207
Data delayed at least 15 minutes, as of Feb 06 2026 14:25 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Company’s activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.

  • Revenue in EUR (TTM)327.87m
  • Net income in EUR4.25m
  • Incorporated--
  • Employees1.42k
  • Location
    Laboratorio Reig Jofre SAGran Capita, 10SANT JOAN DESPI 08970SpainESP
  • Phone+34 934806710
  • Websitehttps://reigjofre.com/es/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
RJF:MCE since
announced
Transaction
value
LeanBio SLDeal completed02 Dec 202502 Dec 2025Deal completed1.49%4.06m
Data delayed at least 15 minutes, as of Feb 06 2026 16:35 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.